Sorafenib and 2-deoxyglucose synergistically inhibit proliferation of both sorafenib-sensitive and -resistant HCC cells by inhibiting ATP production

Gene Expression

Volumn 17, Issue 2, 2017, Pages 129-140

  Reyes, Ryan ^a   Wani, Nissar A ^a   Ghoshal, Kalpana ^a,b   Jacob, Samson T ^a,b   Motiwala, Tasneem ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

2 Deoxyglucose (2DG); Glycolysis; Hepatocellular carcinoma (HCC); Resistance; Sorafenib

Indexed keywords

3 BROMOPYRUVATE; ADENOSINE TRIPHOSPHATE; DEOXYGLUCOSE; GOSSYPOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMATINIB; LONIDAMINE; MAMMALIAN TARGET OF RAPAMYCIN; PYRUVIC ACID DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE PROGRESSION; CELL ENERGY; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; ANALOGS AND DERIVATIVES; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYGLUCOSE; DRUG SYNERGISM; G1 PHASE; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RESTING PHASE, CELL CYCLE;

EID: 85014860775     PISSN: 10522166     EISSN: None     Source Type: Journal    
DOI: 10.3727/105221616X693855     Document Type: Article

References (24)

1. Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, Fabra A, Alvarez-Barrientos A, Fernandez-Salguero P, Fernandez-Rodriguez CM, Giannelli G, Sancho P, Fabregat I. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer 2015;136(4):E161-72.
2. Fiume L, Manerba M, Vettraino M, Di Stefano G. Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. Eur J Pharmacol. 2011;670(1):39-43.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
4. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology 2011;53(3):1020-2.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
6. Villanueva A, Llovet JM. Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib. Clin Cancer Res. 2012;18(7):1824-6.
7. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL. Activation of phosphatidylinositol 3-kinase/ Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011;337(1):155-61.
8. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lower SW, Geffers R, Laufer S, Zender L. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med. 2014;20(10):1138-46.
9. Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, Liu SH, Cheng AL. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer 2013;108(1):72-81.
10. Tesori V, Piscaglia AC, Samengo D, Barba M, Bernardini C, Scatena R, Pontoglio A, Castellini L, Spelbrink JN, Maulucci G, Puglisi MA, Pani G, Gasbarrini A. The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Sci Rep. 2015;5:9149.
11. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25(34):4633-46.
12. Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs 2008;17(10):1533-45.
13. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009;284(46):32015-27.
14. Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST. Stat3- mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 2012;56(1):186-97.
15. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-6.
16. Hardie DG. AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774-85.
17. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005;280(37):32081-9.
18. Hung CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol. 2012;4(12).
19. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol. 2004;53(2):116-22.
20. Zhou H, Shang C, Wang M, Shen T, Kong L, Yu C, Ye Z, Luo Y, Liu L, Li Y, Huang S. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Biochem Pharmacol. 2016;116:39-50.
21. Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23(18):3151-71.
22. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106(1):153-61.
23. Liao G, Gao B, Gao Y, Yang X, Cheng X, Ou Y. Phycocyanin inhibits tumorigenic potential of pancreatic cancer cells: Role of apoptosis and autophagy. Sci Rep. 2016;6:34564.
24. Dazert E, Colombi M, Boldanova T, Moes S, Adametz D, Quagliata L, Roth V, Terracciano L, Heim MH, Jenoe P, Hall MN. Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Proc Natl Acad Sci USA 2016;113(5):1381-6.